Incidence and natural history of pure red cell aplasia in major ABO‐mismatched haematopoietic cell transplantation
暂无分享,去创建一个
S. Parmar | Y. Nieto | U. Popat | M. Qazilbash | A. Alousi | R. Champlin | R. Bassett | C. Hosing | P. Kebriaei | I. Khouri | B. Oran | S. Ciurea | N. Shah | B. Lichtiger | F. Aung | Ping Liu | M. Lima | Qaiser Bashier
[1] Koh Lp,et al. Successful treatment of isohemagglutinin-mediated pure red cell aplasia after ABO-mismatched allogeneic hematopoietic cell transplant using bortezomib. , 2012 .
[2] G. Mufti,et al. Impact of pre-transplant serum ferritin on outcomes of patients with myelodysplastic syndromes or secondary acute myeloid leukaemia receiving reduced intensity conditioning allogeneic haematopoietic stem cell transplantation. , 2010, Leukemia research.
[3] A. Ganser,et al. TRANSPLANTATION AND CELLULAR ENGINEERING: Prolonged isolated red blood cell transfusion requirement after allogeneic blood stem cell transplantation: identification of patients at risk , 2009, Transfusion.
[4] F. Locatelli,et al. Iron overload in patients receiving allogeneic hematopoietic stem cell transplantation: quantification of iron burden by a superconducting quantum interference device (SQUID) and therapeutic effectiveness of phlebotomy. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[5] İ. Yenicesu,et al. Impact of ABO-incompatible donor on early and late outcome of hematopoietic stem cell transplantation. , 2009, Transplantation proceedings.
[6] B. Sandmaier,et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[7] Q. Han,et al. Mesenchymal stem cells for the treatment of refractory pure red cell aplasia after major ABO-incompatible hematopoietic stem cell transplantation , 2009, Annals of Hematology.
[8] T. Karakan,et al. The role of liver biopsy in the workup of liver dysfunction late after SCT: is the role of iron overload underestimated? , 2008, Bone Marrow Transplantation.
[9] P. Thall,et al. Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[10] H. Lazarus,et al. Iron overload in hematopoietic cell transplantation , 2008, Bone Marrow Transplantation.
[11] G. Helbig,et al. Pure red-cell aplasia following major and bi-directional ABO-incompatible allogeneic stem-cell transplantation: recovery of donor-derived erythropoiesis after long-term treatment using different therapeutic strategies , 2007, Annals of Hematology.
[12] K. Zhu,et al. Clinical features and risk factors of pure red cell aplasia following major ABO-incompatible allogeneic hematopoietic stem cell transplantation , 2007, Hematology.
[13] B. George,et al. Pre-transplant reduction of isohaemagglutinin titres by donor group plasma infusion does not reduce the incidence of pure red cell aplasia in major ABO-mismatched transplants , 2005, Bone Marrow Transplantation.
[14] J. P. McCoy,et al. Persistence of recipient plasma cells and anti‐donor isohaemagglutinins in patients with delayed donor erythropoiesis after major ABO incompatible non‐myeloablative haematopoietic cell transplantation , 2005, British journal of haematology.
[15] S. Giralt. Reduced-intensity conditioning regimens for hematologic malignancies: what have we learned over the last 10 years? , 2005, Hematology. American Society of Hematology. Education Program.
[16] G. Helbig,et al. Successful treatment of pure red cell aplasia with repeated, low doses of rituximab in two patients after ABO-incompatible allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia. , 2005, Haematologica.
[17] M. Musso,et al. Donor lymphocyte infusions for refractory pure red cell aplasia relapsing after both autologous and nonmyeloablative allogeneic peripheral stem cell transplantation , 2004, Bone Marrow Transplantation.
[18] K. Cleary,et al. Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. , 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[19] A. Bacigalupo. Third EBMT/AMGEN Workshop on reduced-intensity conditioning allogeneic haemopoietic stem cell transplants (RIC-HSCT), and panel consensus , 2004, Bone Marrow Transplantation.
[20] W. Hörl,et al. Prolonged red cell aplasia after major ABO-incompatible allogeneic hematopoietic stem cell transplantation: removal of persisting isohemagglutinins with Ig-Therasorb® immunoadsorption , 2003, Bone Marrow Transplantation.
[21] H. Greinix,et al. ABO mismatch increases transplant‐related morbidity and mortality in patients given nonmyeloablative allogeneic HPC transplantation , 2003, Transfusion.
[22] A. Barrett,et al. Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation. , 2001, Blood.
[23] R. Witherspoon,et al. Antibody-mediated marrow failure after allogeneic bone marrow transplantation. , 1989, Blood.
[24] R. Storb,et al. ABO‐INCOMPATIBLE MARROW TRANSPLANTS , 1982, Transplantation.